The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2017 | Are we seeing any breakthroughs in the treatment of AML?
Wolfgang Hiddemann, MD, PhD, from Ludwig-Maximilians University, Munich, Germany, talks to us about the current state of treating acute myeloid leukemia (AML), in which current treatment regimens may potentially cure 40% of younger AML patients but there are presently no breakthroughs in the treatment of older AML patients. Prof. Hiddemann explains that apart from midostaurin, currently researched novel drugs and biomarkers have not been observed to have any significant effectiveness and clinical benefit in AML patients. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
